Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Gregg moves to Budget Cmte.

Executive Summary

Senate Health Committee Chairman Judd Gregg (R-N.H.) will retain responsibility over Medicare on a macro level following his move to the chairmanship of the Budget Committee. At his announcement of his plan to seek the Budget Committee's chairmanship Nov. 10, Gregg says he expects Sen. Michael Enzi (R-Wyo.), the most senior member of the Health Committee, to become chair. Health Committee Counsel Steve Irizarry says priorities on the committee's 2005 agenda include drug safety and flu vaccine (1"The Pink Sheet" Nov. 8, 2004, p. 4)...

You may also be interested in...



Vioxx, Drug Safety Issues Top Health Committee Agenda – If Gregg Stays

The Senate Health Committee plans to look into FDA's handling of Vioxx, antidepressant safety and flu vaccine, committee counsel Steve Irizarry said at the Healthcare Distribution Management Association annual meeting in Palm Desert, Calif. Nov. 4

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel